The Company

DxTerity was founded in 2006 with the mission of enabling “Genomics in Everyday Care”. Genomic testing is a key enabler of Precision Medicine, providing a finer level of disease stratification than is possible using traditional medical testing. DxTerity specializes in all aspects of genomic test development including gene signatures optimization, Quality System Regulation (QSR) compliant product development, transfer to manufacturing, test validation, and cGMP manufacturing. Of particular interest for many test developers is our Direct-to-Patient (D2P) clinical research platform that uses digital recruitment, consenting, and monitoring of clinical study participants. D2P is frequently combined with our DxCollect® Fingerstick Collection Kit to obtain blood samples for the development and validation of genomic tests. D2P expands clinical studies to include Anyone, Anytime, Anywhere, and can dramatically lower the cost and speed the process of validating a promising genomic test. In addition to providing contract development services, DxTerity has a line of proprietary multi-variate blood based genomic tests for emergency response, oncology, and autoimmune disease activity monitoring. These tests solve critical unmet needs, demonstrating the impact that genomics are having on healthcare.

Dr. Bob Terbrueggen

DxTerity Diagnostics Founder and CEO

Bob Terbrueggen, PhD, has over 15 years of experience in the development of revolutionary genomic technologies and products.  Bob started out his career at Clinical Micro Sensors (CMS) in Pasadena, CA.  At CMS, Bob was the Director of R&D where he oversaw the development of the world's first bio-electronic DNA detection platform, the e-Sensor.  Motorola acquired CMS in 2000 for $300 million, and the e-Sensor is currently being used to deliver several FDA approved diagnostic tests.  Following the acquisition by Motorola, Bob became Director of Research for Motorola Life Sciences and he spent the next couple of years overseeing the development of next generation genomic platforms until leaving to rejoin the entrepreneurial world of start-ups.  In 2005, Bob helped start NanoBiomics.  NanoBiomics was developing genomic tests for the diagnosis and Prognosis of cancer, and it was named the 2005 best start-up of the year by the Arizona Biotech Association.  In late 2005, less than 9 months after its founding, NanoBiomics was acquired by the Molecular Profiling Institute.  Bob then went on to start DxTerity Diagnostics in early 2006.  Bob is an inventor on 19 approved U.S. patents and more than 20 pending applications.

MEM100001-1

Jim Healy

CFO / COO Co-Founder

Jim Healy, MS, has over 25 years of operations and financial leadership in high technology, software and semiconductor companies, including Cadence Design Systems, Magnify 360, JTA Research and Hughes Electronics. In addition to operational and business development expertise, Jim has strong experience in venture capital funding, mergers and acquisitions and extensive experience in managing large government contracts. As CFO of Hughes Communication Products advanced technology group he lead the growth of government and commercial programs which won over $250 Million of new business and acquisition of $100 Million in revenue Magnavox Radio division for addition to the business unit. As CFO and SVP Business Development for Internet Advertising Start Up Magnify360 he raised capital from seed stage through growth phase and led business development activities for strategic accounts including Intuit, Seagate, ServiceMagic and Autobytel which lead to Top 10 List rating from Frost and Sullivan for marketing automation.

MEM100002

Dr. Aviva Jacobs

Vice President of Product Development

Aviva Jacobs, PhD, PMP, has over 10 years of experience in the in-vitro diagnostics ("IVD") industry with Motorola Life Sciences, which was sold to Osmetech Molecular Diagnostics and GenMark Diagnostics, where she held multiple roles, including Sr. Program Manager, Associate Director of Product Development and Director of Product Technical Services. There she successfully led projects and cross-functional teams resulting in the FDA clearance of genetic tests for Warfarin sensitivity, cystic fibrosis, thrombophilia risk and a respiratory viral panel on the XT-8 System. From 2011 to 2015, she has served as the Director of Product Development at DxTerity Diagnostics, overseeing the development of a genomic test for radiation exposure with Duke University, as part of a competitive contract funded by the US Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA).

MEM100004

Alan Cheeks

Vice President, Operations

Alan Cheeks is an accomplished professional with over 17 years of operations experience as an executive in the laboratory services, clinical diagnostics and drug development industries.  Alan developed and expanded the R&D laboratory and biopharmaceutical services division at IMPATH Inc, lead the clinical trials and esoteric biomarker groups at Quest Diagnostics and managed the global clinical operations for the successful phase I and II clinical trials at Peregrine Pharmaceuticals.  Most recently, Alan was Vice President of Laboratory Operations at Cancer Genetics, which included successful acquisition, FDA clearance and commercialization of an RNA expression-based assay for difficult to diagnose malignancies.  In addition to his extensive experience in the biotechnology industry, Alan has a strong academic research background in carbohydrate metabolism, endocrinology and cell physiology with an emphasis on mathematical modeling and biostatistics.  Alan received his undergraduate and graduate degrees from the University of Southern California.

June Fujimoto

Vice President, Marketing

June has over 14 years of commercial experience in launching new products and in developing new markets in the digital health, personalized medicine and medical device industries at both early stage start-ups as well as at a Fortune 500. Her personalized medicine experience spans work at Crescendo Bioscience, CareDx, Singulex and Clinical Micro Sensors. At Crescendo, she successfully launched and developed the market for the first multi-biomarker blood test for rheumatoid arthritis, which led to the acquisition by Myriad Genetics. At Singulex, she led both upstream marketing in identifying new disease states and new biomarkers to launch and the downstream marketing efforts to include rebranding the division. Prior to that, she worked at Medtronic where she launched multiple implantable defibrillators in a $5B market and developed the endovascular stent graft market. Most recently, she led the commercial efforts at a digital health consumer e-commerce start-up in women's health. Prior to Marketing, she published several papers on her DNA research while at the City of Hope National Medical Center. She has a B.S. in Chemistry from Caltech, an MBA from the UCLA Anderson School and is completing a Professional Certificate in Genetics and Genomics from Stanford.

+ Dr. Bob Terbrueggen

Dr. Bob Terbrueggen

DxTerity Diagnostics Founder and CEO

Bob Terbrueggen, PhD, has over 15 years of experience in the development of revolutionary genomic technologies and products.  Bob started out his career at Clinical Micro Sensors (CMS) in Pasadena, CA.  At CMS, Bob was the Director of R&D where he oversaw the development of the world's first bio-electronic DNA detection platform, the e-Sensor.  Motorola acquired CMS in 2000 for $300 million, and the e-Sensor is currently being used to deliver several FDA approved diagnostic tests.  Following the acquisition by Motorola, Bob became Director of Research for Motorola Life Sciences and he spent the next couple of years overseeing the development of next generation genomic platforms until leaving to rejoin the entrepreneurial world of start-ups.  In 2005, Bob helped start NanoBiomics.  NanoBiomics was developing genomic tests for the diagnosis and Prognosis of cancer, and it was named the 2005 best start-up of the year by the Arizona Biotech Association.  In late 2005, less than 9 months after its founding, NanoBiomics was acquired by the Molecular Profiling Institute.  Bob then went on to start DxTerity Diagnostics in early 2006.  Bob is an inventor on 19 approved U.S. patents and more than 20 pending applications.

MEM100001-1

+ Jim Healy

Jim Healy

CFO / COO Co-Founder

Jim Healy, MS, has over 25 years of operations and financial leadership in high technology, software and semiconductor companies, including Cadence Design Systems, Magnify 360, JTA Research and Hughes Electronics. In addition to operational and business development expertise, Jim has strong experience in venture capital funding, mergers and acquisitions and extensive experience in managing large government contracts. As CFO of Hughes Communication Products advanced technology group he lead the growth of government and commercial programs which won over $250 Million of new business and acquisition of $100 Million in revenue Magnavox Radio division for addition to the business unit. As CFO and SVP Business Development for Internet Advertising Start Up Magnify360 he raised capital from seed stage through growth phase and led business development activities for strategic accounts including Intuit, Seagate, ServiceMagic and Autobytel which lead to Top 10 List rating from Frost and Sullivan for marketing automation.

MEM100002

+ Dr. Aviva Jacobs

Dr. Aviva Jacobs

Vice President of Product Development

Aviva Jacobs, PhD, PMP, has over 10 years of experience in the in-vitro diagnostics ("IVD") industry with Motorola Life Sciences, which was sold to Osmetech Molecular Diagnostics and GenMark Diagnostics, where she held multiple roles, including Sr. Program Manager, Associate Director of Product Development and Director of Product Technical Services. There she successfully led projects and cross-functional teams resulting in the FDA clearance of genetic tests for Warfarin sensitivity, cystic fibrosis, thrombophilia risk and a respiratory viral panel on the XT-8 System. From 2011 to 2015, she has served as the Director of Product Development at DxTerity Diagnostics, overseeing the development of a genomic test for radiation exposure with Duke University, as part of a competitive contract funded by the US Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA).

MEM100004

+ Alan Cheeks

Alan Cheeks

Vice President, Operations

Alan Cheeks is an accomplished professional with over 17 years of operations experience as an executive in the laboratory services, clinical diagnostics and drug development industries.  Alan developed and expanded the R&D laboratory and biopharmaceutical services division at IMPATH Inc, lead the clinical trials and esoteric biomarker groups at Quest Diagnostics and managed the global clinical operations for the successful phase I and II clinical trials at Peregrine Pharmaceuticals.  Most recently, Alan was Vice President of Laboratory Operations at Cancer Genetics, which included successful acquisition, FDA clearance and commercialization of an RNA expression-based assay for difficult to diagnose malignancies.  In addition to his extensive experience in the biotechnology industry, Alan has a strong academic research background in carbohydrate metabolism, endocrinology and cell physiology with an emphasis on mathematical modeling and biostatistics.  Alan received his undergraduate and graduate degrees from the University of Southern California.

+ June Fujimoto

June Fujimoto

Vice President, Marketing

June has over 14 years of commercial experience in launching new products and in developing new markets in the digital health, personalized medicine and medical device industries at both early stage start-ups as well as at a Fortune 500. Her personalized medicine experience spans work at Crescendo Bioscience, CareDx, Singulex and Clinical Micro Sensors. At Crescendo, she successfully launched and developed the market for the first multi-biomarker blood test for rheumatoid arthritis, which led to the acquisition by Myriad Genetics. At Singulex, she led both upstream marketing in identifying new disease states and new biomarkers to launch and the downstream marketing efforts to include rebranding the division. Prior to that, she worked at Medtronic where she launched multiple implantable defibrillators in a $5B market and developed the endovascular stent graft market. Most recently, she led the commercial efforts at a digital health consumer e-commerce start-up in women's health. Prior to Marketing, she published several papers on her DNA research while at the City of Hope National Medical Center. She has a B.S. in Chemistry from Caltech, an MBA from the UCLA Anderson School and is completing a Professional Certificate in Genetics and Genomics from Stanford.